Search
Menu
Home
HTB
2010
June
HTB
June 2010
Contents
Editorial
Volume 11 Number 5/6 May/June 2010
Conference reports
2nd Joint Conference of BHIVA with BASHH, 20-23 April 2010, Manchester
HAART use among women in UK receiving treatment prior to conception
Duration of ruptured membranes and vertical transmission in the UK
Significant rates of unplanned pregnancies among young women born with HIV
Route of HCV transmission in HIV-positive gay men is unlikely to be from semen
75% HIV-positive children have insufficient levels of Vitamin D
Increase in LGV cases in gay men reported in the UK
High rates of osteopenia and osteoporosis: importance of DEXA monitoring
Summaries of other studies
11th International Workshop on Clinical Pharmacology of HIV Therapy, 7-9 April, 2010, Sorrento, Italy
Atazanavir absorption maximised with food
Methadone levels reduced moderately by rilpivirine
Maraviroc 150mg once-daily achieves target concentrations with atazanavir/ritonavir
Raltegravir and unboosted atazanavir
Raltegravir dose adjustment not required for patients on dialysis
Raltegravir and darunavir pharmacokinetics in liver disease
Tenofovir may require closer renal monitoring in older patients
Effect of age on atazanavir, darunavir, raltegravir and etravirine
Proposed approach to measuring TDM for raltegravir
Increased bilirubin levels when atazanavir is dosed twice-daily
17th Conference on Retroviruses and Opportunistic Infections (CROI) 16-19 February 2010, San Francisco
HIV reinfection cases reported at CROI
Hepatitis studies: IL28B genetics, HCV survival, FibroScan in acute HCV, MSM reinfection and responses to transplantation
Poor bioequivalence with crushed and dissolved tablets
Initial PK, safety and 12 week efficacy of raltegravir chewable tablets in children 6-11 years
PK of efavirenz in children dosed according to WHO weight bands
Virological and immunological responses in infants enrolled in the CHER trial
Darunavir-associated mutations in PI-naive and PI-experienced children in the UK
HIV persistence, raltegravir/maraviroc intensification and immunology
Antiretrovirals
START study launched and endorsed by broad community support: over 140 community organisations sign letter to US guideline panel
FDA safety updates to antiretroviral labels
Development of apricitabine halted without finding backer for Phase 3
Treatment access
FDA approval of generic ARVs
U.S. government leading backlash against AIDS funding
Evidence from six countries confirms fears of People Living With HIV/AIDS: treatment rationing is escalating
Launch of the 10th funding round and other outcomes from the Global Fund
Pregnancy
Pregnancy outcomes with efavirenz
Basic science and immunology
The antiviral impact of CD8 T cells: much ado about the mechanism
Bad to the bone marrow?
Cell-free vs cell-associated HIV transmission
Coagulation and inflammatory biomarkers in children and adolescents with HIV
Pre-infection CD8 T cells targeting HIV linked to lower post-infection viral load
Treatment advocacy
The HIV Research Catalyst Forum: treatment, prevention, advocacy
Experimental HCV drugs for HIV/HCV coinfected people: workshop on trial design
AIDS activists detained by Tanzanian authorities at World Economic Forum on Africa
Other news
China lifts travel ban on people with HIV
Malawian courts 14-year sentence for gay men widely condemned
Uganda law proposes death penalty for homosexuality: can international reaction and vulnerability of treatment access programmes help?
PDFs
Volume 11 Number 3/ May/April 2010 PDF
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
HIV diagnoses in England jumps by 51% in 2023: missing targets and highlighting disparities in access to care
6 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage